Proliferation of vascular smooth muscle cells (SMC) contributes to formation of the complicated human atherosclerotic plaque. These lesions also contain macrophages, known to secrete SMC mitogens, and T lymphocytes. Many of the SMC in the lesions express class II major histocompatibility antigens, an indication that activated T cells secrete immune IFN-'y locally in the plaque. We therefore studied the effect of IFN-y on the proliferation of cultured SMC derived from adult human blood vessels. IFN--y (1,000 U/ml) reduced j3Hjthymidine (TdR) incorporation into DNA by SMC stimulated with the well-defined mitogens IL 1 (from 15.3±0.7 to 6.2±0.7 dpm X 10-3/24 h) or platelet-derived growth factor (PDGF) (from 18.5±1.0 to 7.3±0.7 dpm X 10-3/24 h). Kinetic and nuclear labeling studies indicated that this effect of IFN-'y was not due to altered thymidine transport or specific radioactivity of TdR in the cell. In longer term experiments (4-16 d) IFN-'y prevented net DNA accumulation by SMC cultures stimulated by PDGF. IFN--y also delayed (from 30 to 60 min) the time to peak level of c-fos RNA in IL 1-treated SMC.
Introduction
In humans, the formation of complicated atheromatous plaques may require decades. One important feature of this long-term process is excessive proliferation ofvascular smooth muscle cells (SMC)' (1) . Much work over the last decade has focused on the characterization of mediators that promote growth of these cells. For example, adherent platelets or infiltrating monocytes are a source of several SMC mitogens including platelet-derived growth factor (PDGF) (1) (2) (3) (4) , IL 1 (5) , and transforming growth factor-alpha (6) . Potential inhibitors of SMC proliferation have generally received less attention, although the degree of net SMC growth is likely to be determined by the balance between positive and negative stimuli over the years often required to form these lesions. Heparinlike molecules synthesized by vascular wall cells provide one example of a potential endogenous inhibitor of SMC proliferation (7) . We have recently found that PGE2, a product ofboth vascular endothelial and smooth muscle cells can limit proliferation of human SMC in the short term (< 4 d), after which these cells become refractory to this effect (5) .
Another potential negative regulator of SMC growth in vivo is suggested by the surprising demonstration of immunocompetent cells in advanced human atherosclerotic lesions. Recent histological studies using well-defined, cell type-specific antisera not only confirmed the long-suspected presence of macrophages, but disclosed that T lymphocytes comprise up to 20% of the cells in regions of human atheromata (8) (9) (10) . Many of the SMC in these lesions also bear class II major histocompatibility antigens (HLA DR' SMC) (11) . Under usual circumstances, vascular SMC do not express these antigens, and the only known inducer of class II MHC expression in these cells is immune IFN, also known as gamma IFN (IFN-y) (12) (13) (14) . T lymphocytes are a potential source of IFN-"y within the atheroma (15) (16) (17) . Taken together, these various findings indicate that human plaques contain a population of SMC that have been exposed to this cytokine.
Because IFN-'y is antiproliferative for some cell types, including human vascular endothelial cells (18) (19) (20) (21) (22) (23) (24) (25) (26) , we tested the hypothesis that this cytokine can also inhibit growth of human SMC. This issue requires careful investigation because IFN-y can interfere with thymidine transport in some cell types, and thus confound methods commonly used to assess the growth of cultured cells (27) . Furthermore, IFN-Y, under certain circumstances, can promote the growth of some mesenchymal cells (28). We show here that IFN-y inhibits the IL 1or PDGF-stimulated growth of SMC cultured from adult humans, modulates the kinetics of c-fos mRNA induction by mitogens, and activates expression by SMC of the 2'-5'-oligoadenylate synthetase gene that encodes an enzyme thought to 1. Abbreviations used in this paper: HSVSMC, human saphenous vein smooth muscle cells; IT, serum-free chemically defined medium supplemented with 1 gM insulin and 5 Ag/ml transferrin; Oligo-A, oligoadenylate; PDGF, platelet-derived growth factor; PDS, plasma-derived serum; SMC, smooth muscle cells; TdR, tritiated thymidine. mediate certain effects of IFN on mammalian cells (22, 23, 25) . These results suggest hitherto unsuspected interplay between cells ofthe immune system and the regulation of growth of human SMC. Modulation of the responsiveness of SMC to mitogenic stimuli by IFN-y may contribute to regulation of the growth state and other SMC functions in the pathogenesis of human vascular diseases.
Methods
Cell culture and characterization (a) Human saphenous vein smooth muscle cells. Human saphenous vein smooth muscle cells (HSVSMC) were isolated from outgrowths of explants of unused portions of veins harvested for coronary artery bypass surgery (5) . The endothelium was removed enzymatically and the adventitia was removed by blunt and sharp dissection before culture of the explants. This use of normally discarded tissue was approved by the Human Investigation Review Committee of New England Medical Center. The cells were maintained in DME that contains 5.5 mM glucose, 25 mM Hepes (M. A. Bioproducts, Walkersville, MD), and 10% FCS (Hyclone Laboratories, Logan, UT).
Low concentrations of bacterial endotoxin (< 100 pg/ml) can activate these cells to produce endogenous IL 1 (29) . Endotoxin contamination oftissue culture reagents could complicate study ofthe effects of exogenous cytokines. Therefore, constituents of tissue culture media were screened for endotoxin contamination using the quantitative chromogenic Limulus amoebocyte lysate assay (QCL 1000; M. A. Bioproducts). Only materials with endotoxin levels < 40 pg/ml are used in these experiments. The endotoxin antagonist polymyxin B (10 Mg/ml; Sigma Chemical Co., St. Louis, MO) was included in most experimental incubations, although this precaution does not necessarily neutralize all endotoxins (30) .
The cells cultured from saphenous veins (passages 3-5) exhibited typical morphologic characteristics ofvascular smooth muscle in vitro, including a pattern of growth in hills and valleys (31) . Even after several passages in culture many of these cells stained with HHF-35, a MAb that selectively recognizes muscle forms of actin and that does not react with endothelial cells or fibroblasts (32).
(b) Human arterial smooth muscle cells. Aortic SMC were isolated enzymatically from the inner third of the tunica media of human aortic tissues obtained from organ donors, with the cooperation of the New England Organ Bank (5) . The adventitia and abluminal twothirds of the tunica media were removed before dissociation of the tissue with collagenase. Culture and characterization of these cells was as described above for venous SMC. Assay ofgrowth ofhuman smooth muscle cells (a) Thymidine uptake. For growth assays, cells were subcultured into 96-multi-well plates at 1.25-2.30 X 105 cells/cm2 and used for experiments 2 d after subculture. Before initiation of growth studies, these cultures were placed for one day in medium composed ofequal parts of DME and Ham's F-12 medium (Gibco, Grand Island, NY) (DME/F-12) lacking serum but supplemented with insulin (1 MM) and transferrin (5 ,g/ml) (Collaborative Research, Bedford, MA), a medium denoted IT (33) . This incubation in serum-free medium deprives the cells of serum-associated mitogens, arrests growth, and synchronizes cell proliferation in response to mitogens being assayed. Cultures prepared in this manner exhibited little or no basal c-fos mRNA level but rapid and brief c-fos expression after mitogen exposure, consistent with their initial quiescence and synchronous response to growth stimuli (5) . Cultures were then incubated at 37°C for 2 d under various conditions and the incorporation of [3H]thymidine (TdR) (6.7 Ci/mmol; ICN Radiochemicals, Irvine, CA) was measured in these short-term assays by addition ofthe [3H]TdR (0.25 MCi/ml) during the second 24 h ofthe 2-d incubation. This schedule of labeling maximizes TdR incorpora-tion by mitogen-stimulated HSVSMC. At the end of the incubation unincorporated precursor was removed by washing with distilled water cell residues collected on nitrocellulose paper by an automated cell harvester. Radioactivity was measured by liquid scintillation spectroscopy, and efficiency of counting was determined by use of an external standard.
(b) DNA assay. DNA measurements were made on lysates of cell layers by a fluorimetric procedure based on binding of bisbenzamide (5, 34) . After being washed with HBSS that lacks Ca2+ and Mg2", the monolayers were treated with cold EDTA (10 mM, pH 12.3) and incubated at 370C for 20 min. I M KH2PO4 was added to neutralize the lysate. After addition of bisbenzamide (Hoecht 33258; Calbiochem-Behring Corp., La Jolla, CA) diluted to 200 ng/ml in 100 mM NaCl and 10 mM Tris pH 7.0, the samples were read in an automated microplate fluorometer (Dynatech Microfluor, Dynatech Laboratories, Alexandria, VA) with calf thymus DNA (Sigma Chemical Co.) as standard. This assay is sensitive to 50 ng of DNA, and correlation coefficients for standard curves were > 0.99.
(c) Assessment of DNA synthesis by thymidine nuclear labeling. Target cells were plated at 3.0 X 104 cells/cm2 on tissue culture chamber slides (Lab-Tek; Miles Laboratories, Naperville, IL) and growth arrested for 4 d as described above. 18 h after addition of test samples [3H]TdR (2 MCi/well) was added to each chamber. After 24 h, the cell layer was washed with HBSS, fixed in absolute methanol for 45 min, washed, and air dried. The slides were dipped in emulsion NBT-2 (Eastman Kodak, Rochester, NY), air dried, and stored at 4°C in dark boxes with dessicant. After 12 d, these slides were developed in D-19, fixed in Ektaflow (Eastman Kodak) and counterstained with hematoxylin (type III; Sigma Chemical Co.) to visualize unlabeled nuclei. The labeling index was calculated by counting 15 random high-power microscopic fields (400X, 30-90 nuclei/field) in each condition to quantitate the fraction of cells passing through S phase during the time of exposure to labeled precursor. This method is little affected by variations in the specific radioactivity of the TdR precursor pool, which depends on thymidine transport and other factors. The tubes were agitated vigorously for 30 min at room temperature. A further 2 ml ofthe glycine-HCI, was added and the alumina pelleted by centrifugation for 5 min at 1,500 g). 32p in phosphatase-resistant oligoadenylate cores was determined by Cerenkov counting.
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Assessment ofspecific mRNA levels (a) Isolation ofRNA and Northern analysis. Cultured cells were lysed in guanidinium isothiocyanate and RNA was purified by acid phenol extraction (36) . RNA concentration was determined from the A260, and A260/A280 ratios were > 2. RNA was electrophoresed in agarose gels (1.2%) containing 2.2 M formaldehyde, transferred to nylon membranes (Hybond-N; Amersham Co., Arlington Heights, IL), and immobilized by shortwave ultraviolet illumination. The membranes were prehybridized for at least 2 h before hybridization according to standard protocols with 32P-labeled DNA probes labeled by random hexanucleotide priming (37) to specific activities > 108 cpm/gg DNA, and autoradiographed. After a l-d incubation in IT (a chemically-defined serum-free medium), the medium was replaced with either fresh IT (a) or DME supplemented with plasma-derived serum (PDS, 5%) (an undefined medium low in intrinsic mitogenic: activity, but that contains many plasma factors lacking in the chemically-defined media) (v). All conditions contained I ,ug/ml indomethacin. The effect of 1,000 U/ml rIFN-,y was determined alone or with 1.0 ng/ml rIL I aY or rPDGF, sis ( 10 ng/ml) in both of the media. TdR incorporation was measured over the second 24-h period of a 2-d incubation. The data are mean±SD, n = 8. v-sis product (PDGF) was supplied by Amgen Biologicals, Thousand Oaks, CA.
Cytokines and antibodies

Results
Interferon-y inhibits mitogen-induced [3H]TdR incorporation in HSVSMC. 1,000 U/ml IFN-y inhibited [3H]TdR incorporation by HSVSMC stimulated with either rPDGF or rIL 1 (Fig. 1 , and data not shown). This effect of IFN-'y was concentration dependent (Fig. 2) and occurred in cultures maintained in a defined serum-free medium containing insulin and transferrin (IT), or in plasma-derived serum (PDS, 5%), a supplement low in intrinsic mitogenic activity, but one that contains many plasma factors lacking in the chemically defined medium IT (40) (Fig. 1 ). In certain cell types, IFN-y inhibits thymidine transport (27) . To assess whether the effect of IFN-'y on [3H]TdR incorporation in HSVSMC reflected an IFN-'y-induced reduction in [3H]TdR transport and consequent alteration in the specific radioactivity of the precursor pool for DNA synthesis, we measured TdR transport in the absence or presence of IFN-y. In synchronized SMC cultures 1 d after mitogen stimulation, [3H]TdR incorporation into the acid-insoluble fraction (DNA) increased linearly, whereas the [3H]TdR in the acid-soluble fraction (cytoplasmic pool) reached a plateau in < 5 min (data not shown). We measured acid-soluble radioactivity after a 2-min incubation period as an index of the initial velocity of thymidine transport. Treatment with IFN-y did not significantly alter this process in cells treated with rIL 1, but produced a concentration-dependent increase in the rate of [3H]-TdR uptake into rPDGF-stimulated HSVSMC (data not shown). These observations render unlikely the possibility that IFN-'y inhibits [3H]TdR incorporation into acid-insoluble ra- of HSVSMC used in the autoradiographic experiment above were studied in parallel for incorporation of radioactive precursor TdR.
SMC were plated at 6.1 X i0s cells/0.32 cm2 in DME supplemented with 10% FCS for 1 d. After a l-d incubation in IT to produce growth arrest, the medium was replaced with either fresh IT, or IT supplemented with 10 ng/ml rPDGF, si,, 10 ng/ml rPDGFsi. + HSVSMC were plated at 9.6 X 103 cells/0.32 cm2 in DME-10% FCS. After a 2-d incubation in IT, the medium was replaced with DME supplemented with 5% PDS, with or without 1,000 U/ml IFN-y and preincubation continued for 4 d. The IFN-y present during preincubation was then removed and replaced with medium alone (control), 10 ng/ml PDGF, 10 ng/ml PDGF + 1,000 U/ml IFN-^y, or 1,000 U/ml IFN-'y alone. DNA content of the cultures was measured after 8 d. Data are mean±SD, n = 8. * A 95% significance level was obtained by ANOVA between the following groups: -IFN and +IFN pretreatment, control and PDGF, and PDGF and PDGF + IFN.
cursor pool-specific radioactivity do not account for the reduction in TdR uptake produced by IFN-,y.
IFN-,y inhibits nuclear labeling with [3H]TdR in mitogenstimulated HSVSMC. As an independent means of assessing the effect of IFN-'y on HSVSMC proliferation we performed autoradiography of cells treated with IFN-'y and mitogen in the presence of [3H]TdR. This technique labels all cells that have traversed S phase and is insensitive to the confounding influence of transport phenomena and other factors that may alter the specific radioactivity of the precursor pool for DNA synthesis. Treatment of cells with 1,000 U/ml IFN-'y prevented the mitogen-induced increase in labeling index, determined by autoradiography ( Figs. 3 and 4 A) . In parallel incubations of HSVSMC from the same isolate, 1,000 U/ml IFN-7 inhibited [3H]TdR incorporation ( Fig. 4 B) (Fig. 5 ). In cultures treated with PDGF, DNA content increased during 16 d in culture. The addition of IFN-' completely prevented this accumulation of DNA with time. The inhibitory effect of IFN-'y is unlikely to Figure 3 . rIFN-y inhibits nuclear labeling by [3H]TdR in HSVSMC stimulated by rPDGF. HSVSMC were sub-cultured at 6.0 X 10' cells/2.0 cm2 into four-chambered tissue-culture glass slides in DME supplemented with 10% FCS. After a 4-d incubation in IT, the medium was replaced with either (A) fresh IT alone, (B) IT supplemented with 5 ng/ml rPDGF-,is, (C) 1,000 U/ml rIFN-y alone, or (D) rPDGF,.,i + rIFN-'y. The slides were treated for autoradiography, and counterstained with hematoxylin. The photomicrographs show representative fields, nuclei resulting from cell divisions during exposure to the labeled precursor TdR are darkened by the silver grains. DAYS Figure 5 . rIFN-y inhibits accumulation of DNA by cultures of PDGF-treated HSVSMC. Replicate cultures of HSVSMC were plated at 9.6 X 103 cells/0.32 cm2 in DME supplemented with 10% FCS. After a 2-d incubation in IT to produce growth arrest, the medium was replaced with DME supplemented with 5% PDS alone (o) or with 10 ng/ml rPDGF1.,i (i), 10 ng/ml rPDGFVSi, + . Further experiments showed that treatment for 2 24 h with as little as 1 U/ml of IFN-a or 10 U/ml of IFN-'y induced oligo-A synthetase mRNA (data not shown). The Type I IFN's (a and /3) induced higher levels of oligo-A synthetase mRNA than IFN-y, as previously observed in other cells. The response to IFN-/3 was abolished by anti-IFN-/3 antiserum, indicating the selectivity of this induction (Fig. 7) . To determine whether the induced oligo A synthetase mRNA correlated with appearance of enzyme activity, we assayed the enzyme in extracts of HSVSMC treated for 24 h with IFN-a, IFN-f3, or IFN--y (0.1-1,000 U/ml). IFN-a and IFN-,8 treatment induced oligo-A synthetake activity in a concentration-dependent manner (Fig. 8 ). In agreement with the steady-state RNA levels (Fig. 7) , IFN-'y induced less oligo-A synthetase activity than the type I IFN (Fig. 8 ).
Discussion
This study demonstrated, using several independent criteria, that IFN--y treatment inhibits the responses of cultured human vascular smooth muscle cells to IL 1 and PDGF, two growth factors ofparticular significance because they can be produced by cells of the vessel wall (5, (41) (42) (43) . IFN-'y added simultaneously with mitogen delayed the mitogen-induced increase in c-fos oncogene mRNA levels, an early consequence of growth factor activation of cells that characteristically occurs within minutes (Fig; 6 ). Prolonged exposure of SMC to IFN-7 (over days to weeks) prevented mitogen-induced DNA accumulabe attributable to cytotoxicity of the cytokine, as HSVSMC treated with IFN-7 for 4 d and then stimulated with PDGF in the absence of IFN-'y still accumulated DNA (Table I ). In addition, phase-contrast microscopy or photometric examination of HSVSMC cultures stained with crystal violet failed to demonstrate cytopathic effect or attrition of cells exposed to IFN-'y (data not shown). Together, the above data indicate that IFN-'y inhibits proliferation of HSVSMC selectively, rather than by nonspecific cytotoxic effect. IFN-,y alters the kinetics ofc-fos protooncogene mRNA induction after mitogen stimulation. We have previously shown in HSVSMC that both IL 1 and PDGF induce a transient increase in c-fos mRNA levels, which peak within 15-30 min after addition of mitogen to quiescent cultures (5) . Simultaneous addition of 1,000 U/ml IFN-'y and 1.0 ng/tnl IL 1 a to growth-arrested cultures of HSVSMC delayed the c-fos response twofold, so that the peak level occurred 60 min after mitogen addition (Fig. 6 ). Pretreatment with IFN-y for 24 h did not alter the rate of accumulation of IL 1-induced c-fos mRNA, but did reduce the maximum steady-state level ofthis mRNA after IL 1 treatment (data not shown).
IFNs induce 2-5' oligoadenylate synthetase gene expression in HSVSMC. In certain other cell types induction of the 2T-5'-oligoadenylate synthetase enzyme (oligo-A synthetase) and consequent increase in the intracellular level of its products, oligoadenylate oligomers, may mediate the antiviral as well as the antiproliferative effect of IFNs (22, 23, 25) . Under basal conditions, cultured HSVSMC contain no oligo-A synthetase mRNA or enzyme activity. HSVSMC treated for 72 h with IFN-a, IFN-,B, or IFN-y (each at 1,000 U/ml) contained oligo A synthetase mRNA that comigrated with the three sizes of transcript found in human diploid fibroblasts (WI-38 cells) treated with cycloheximide, poly I-poly C, and IFN-/3 (25) with IFN-a, IFN-fl, or 1,000 U/ml each IFN-'y. Some cells were also incubated with 1,000 U/ml IFN-(# that had been treated with either bovine anti-IFN-P antiserum (1: 166 dilution) or with nonimmune bovine serum. 20 ,g of RNA was subjected to Northern analysis and probed for 2'-5'-oligoadenylate sequences (top). The arrows indicate the position of the 28S and 18S ribosomal subunits. In addition, RNA from W138 fibroblasts that had been treated for 4 h with cycloheximide, poly I-poly C, and IFN-fB (WI+), or control cells (WI-) was electrophoresed as positive and negative controls, respectively.
The blot was stripped and rehybridized with f3-tubulin probe (bottom), which confirms the integrity of the RNA on the blot, and shows that approximately equal amounts of RNA were loaded in each lane. tion (Fig. 5 ). IFN-'y thus affects both early and late events in pathways ofmitogen stimulation of SMC, and may inhibit cell proliferation by multiple mechanisms. Our finding that IFN-y induces oligo-A synthetase mRNA levels and enzyme activity in human vascular SMC suggests one possible mechanism of growth inhibition. This enzyme polymerizes ATP into oligomers that activate intracellular endoribonucleases that may degrade RNA, leading to reduced protein synthesis and thus contribute to both the antiviral and antiproliferative effects of IFNs (22, 23, 25) . The finding that IFNs lack these activities in cell strains deficient in this RNAase supports this concept (22, 23) . In bovine SMC, serum-associated mitogens regulate the levels of c-myc and certain other growth-related mRNA species by decreased degradation rather than increased transcription (44) . IFNs The experiments reported here establish the effects ofpurified cytokines on homogeneous cell cultures. Although extrapolation of our results to intact human tissues remains hypothetical, Hansson and colleagues have recently shown that IFN-'y inhibits rat SMC proliferation in vitro and in vivo after balloon catheter injury to the carotid artery (13). Their elegant in vivo experiments in rats suggest that class II-bearing SMC (i.e., the very cells likely to have been exposed to IFN-7) proliferate less than cells which lack these determinants. In rabbits fed an atherogenic diet, concurrent administration of IFN inducers retards the development of aortic lesions (45) . These various results in intact animals indicate that our results on cultured human cells may well apply in vivo.
These results may be ofparticular pathophysiologic significance in the context of human atherosclerosis. Jonasson et al. (15) (16) (17) . Because many of the smooth muscle cells in lesions express surface HLA-DR antigens (1 1) , and IFN-'y is the only cytokine known to induce these antigens on human vascular cells (12) (13) (14) , it is likely that leukocytes in the complicated human atherosclerotic plaque are activated and secrete this mediator locally.
Three major cell types found in the advanced human atheroma (endothelial cells, SMC, and mononuclear phagocytes) can each express IL 1 genes in vitro (15, 29, 46) . We recently demonstrated that IL 1 can be a potent stimulus for proliferation of human SMC (5). These findings revealed a novel link between mediators of the inflammatory and immune re-sponses and the control of proliferation of arterial SMC. The usual requirement for IL 1 in T cell activation together with evidence for activation of T cells within atheromata suggests the presence of this cytokine in the human atherosclerotic lesion.
If local IL 1 secretion contributes to the pathogenesis of human vascular diseases, our recent findings raise an interesting question. Because IL 1 begets further IL 1 gene expression in three cell types prominent in human atheromata (47) (48) (49) , what prevents positive feedback from amplifying and propagating the inflammatory response or SMC proliferation in an uncontrolled fashion? IL 1 characteristically stimulates the cyclooxygenase pathway of target tissues. The major arachidonate product in human SMC treated with IL 1 is PGE2. We have found that PGEI or PGE2 inhibits the responsiveness of human SMC to the mitogenic effect of IL 1 during short term incubations (< 4 d). Concomitant treatment of SMC with a cyclooxygenase inhibitor blocks the IL 1-induced increase in PGE2 synthesis and uncovers IL l's direct mitogenic effect on SMC (5) . Thus IL l's mitogenic effect on SMC is mitigated (in the short term at least) by simultaneous induction ofa negative regulatory factor, PGE2. Because IFN-'y is produced by T cells that may be activated in part by IL 1, this pathway may provide another example of growth inhibition facilitated by IL 1. The results of our long-term experiments indicate that this inhibitory effect is more sustained than that due to PGE2. The formation of the human atheroma is a prolonged process, its progression must depend in part on the dynamic balance between stimuli that promote and those which retard SMC growth. Our present data indicate that IFN-'y may be one pathophysiologically significant inhibitor of SMC growth in the setting of the atherosclerotic plaque.
These various observations suggest a scenario in which a communication network mediated by inflammatory cytokines could play key roles in intercellular signalling in vascular pathophysiology. T cells, attracted to the developing atherosclerotic lesion by locally produced cytokines such as IL 1, become activated. The pathway of T cell activation in the atheroma is incompletely understood at present. Although endogenous IL 1 might contribute to activation of T cells, this process usually also requires specific antigenic stimulus to induce production of activation-associated lymphokines such as IL 2 and IFN-T (15) . Both the nature ofthe antigenic trigger to T cell activation and the stimuli for local IL 1 gene expression in the vessel wall are currently unknown, and are fruitful subjects for further investigation. In any case, it is likely that some leukocytes in the plaque are activated to produce IFN--y, since immune interferon appears necessary to induce HLA-DR antigen expression by SMC as found in the human lesion. Endothelial cells can produce type I IFN activity (50), but T lymphocytes are the probable source of immune IFN (a type II IFN) which activates HLA-DR expression. As shown here, the locally produced IFN-y could then antagonize IL 1or PDGF-induced SMC proliferation. Either cells of the vessel wall or infiltrating leukocytes could provide local sources of both of these well-characterized mitogens. The view of atherogenesis that emerges from this fusion of in vitro observations with results of studies on human tissues in situ highlights the dynamic aspects ofthe formation ofthese lesions, the potential importance of cells of the vessel wall themselves as sources of regulatory signals, and of interactions between leukocytes and SMC. The results presented here further illustrate how alter-ations in the balance of locally produced stimulatory and inhibitory cytokine messages may influence growth control and other aspects of vascular homeostasis.
